Loading organizations...
§ Venture Capital · San Francisco, CA, USA
Venture capital fund investing in early-stage life science and biotechnology innovations across the U.S., Canada, and Europe.
Key people at 7G BioVentures.
7G BioVentures is a venture fund concentrating on first-in-class life science innovations. Their primary investment focus areas include healthcare innovation, prevention, and digital healthcare. Geographically, they primarily invest across the U.S., Canada, and Europe.
7G BioVentures' core mission is to empower top scientists, clinicians, and entrepreneurs to translate breakthrough discoveries into life-saving products. They achieve this by providing venture capital to companies developing first-in-class life science innovations, leveraging their partners' decades of domain expertise and strong track records in the sector.
7G BioVentures specifically targets "first-in-class life science innovations" that fall within the broader categories of healthcare innovation, prevention, and digital healthcare. They seek opportunities that have the potential to develop into life-saving products, primarily in North America and Europe.
7G BioVentures operates with a philosophy they term "Patient Capital for Global Patients." This approach is underpinned by seven core values: Gold, Glory, Goodness, Grit, Gratitude, Grandness, and Grace, indicating a long-term, values-driven investment strategy within the life sciences.
7G BioVentures is led by partners with extensive life science investment expertise. Key individuals include Vincent Xiang, PhD MBA (Founding Partner), Samuel Wu, MD PhD (Partner), and Tassel Chen, CPA. Their combined experience aims to guide the translation of breakthrough discoveries into impactful healthcare products.
7G BioVentures is a venture fund concentrating on first-in-class life science innovations. Their primary investment focus areas include healthcare innovation, prevention, and digital healthcare. Geographically, they primarily invest across the U.S., Canada, and Europe.
7G BioVentures' core mission is to empower top scientists, clinicians, and entrepreneurs to translate breakthrough discoveries into life-saving products. They achieve this by providing venture capital to companies developing first-in-class life science innovations, leveraging their partners' decades of domain expertise and strong track records in the sector.
7G BioVentures specifically targets "first-in-class life science innovations" that fall within the broader categories of healthcare innovation, prevention, and digital healthcare. They seek opportunities that have the potential to develop into life-saving products, primarily in North America and Europe.
7G BioVentures operates with a philosophy they term "Patient Capital for Global Patients." This approach is underpinned by seven core values: Gold, Glory, Goodness, Grit, Gratitude, Grandness, and Grace, indicating a long-term, values-driven investment strategy within the life sciences.
7G BioVentures is led by partners with extensive life science investment expertise. Key individuals include Vincent Xiang, PhD MBA (Founding Partner), Samuel Wu, MD PhD (Partner), and Tassel Chen, CPA. Their combined experience aims to guide the translation of breakthrough discoveries into impactful healthcare products.
7G BioVentures is a Belmont, California-based venture capital firm that invests in first-in-class life science and biotechnology innovations across the United States, Canada, and Europe. The organization provides financial backing and strategic support to early-stage startups developing novel therapeutics and advanced healthcare solutions. Operating with a focus on translating clinical discoveries into commercial products, the firm currently manages 1 closed venture fund. In November 2023, the entity filed an amended SEC Form D for exempt securities offerings to facilitate additional capital allocation from limited partners. The firm's investment and executive team includes recognizable professionals such as Managing Member Wenkai Xiang, Partner Samuel Wu, Venture Partner Sam Khatami, and Chief Financial Officer Tassel Chen. The exact founding year and the identities of the original founders are currently undisclosed.
Key people at 7G BioVentures.
7G BioVentures has 1 tracked investment across 1 company. The latest tracked deal is $8.0M Series A in KayoThera in March 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 16, 2022 | KayoThera | $8.0M Series A | KEN Mohler | 7G Bioventures, BioAdvance |
7G BioVentures is a venture capital firm specializing in first-in-class life science innovations across the U.S., Canada, and Europe. Their mission centers on empowering leading scientists, clinicians, and entrepreneurs to translate breakthrough biomedical discoveries into life-saving products. The firm’s investment philosophy focuses on backing pioneering technologies in life sciences that have the potential to create significant clinical impact. By targeting early-stage, innovative ventures, 7G BioVentures plays a critical role in advancing novel therapeutics and medical technologies, thereby influencing the startup ecosystem within the life sciences sector[1][3].
Founded with partners possessing decades of experience in life science investing, 7G BioVentures leverages deep domain expertise to identify and support transformative innovations. While specific founding year details are not publicly disclosed, the firm is led by key partners such as Dr. Samuel Wu and Sam Khatami, who bring strong track records in the field. The firm’s evolution has maintained a clear focus on first-in-class innovations, emphasizing translational science that bridges early discovery with clinical application[1][3][4].
7G BioVentures rides the wave of increasing demand for innovative biomedical solutions driven by advances in genomics, personalized medicine, and novel therapeutic modalities. The timing is critical as the life sciences sector experiences rapid scientific breakthroughs coupled with growing capital inflows. Market forces such as aging populations, unmet medical needs, and regulatory incentives favor investment in pioneering biotech startups. By focusing on first-in-class innovations, 7G BioVentures helps accelerate the translation of cutting-edge science into impactful healthcare products, thereby shaping the broader ecosystem of life science entrepreneurship and innovation[1][3].
Looking ahead, 7G BioVentures is well-positioned to capitalize on emerging trends in biotechnology, including gene editing, cell therapies, and AI-driven drug discovery. Their continued focus on early-stage, high-impact innovations suggests they will remain influential in nurturing startups that redefine therapeutic paradigms. As the life sciences landscape evolves, the firm’s expertise and network will likely expand their ability to drive breakthrough products to market, reinforcing their role as a key catalyst in the biomedical venture capital space[1][3].
In summary, 7G BioVentures stands out as a specialized, experienced venture fund dedicated to advancing transformative life science innovations, playing a pivotal role in bridging scientific discovery and clinical impact.
